7 months ago
Aragen Expands Biologics in India
Aragen Life Sciences is a company that helps other pharmaceutical companies develop and make medicines.
They are moving more of their work to India because there is a growing need for complex biologics and other advanced therapies.
India has a lot of talent in chemistry and engineering, and Aragen is investing in new technologies and training to expand into biology and biologics.
They have received $100 million to build new capabilities in India, and many global drugmakers are shifting some of their work from China to India.
Aragen wants to make sure they maintain high quality standards to compete with other global hubs.
They are also considering going public in the future.
Aragen Life Sciences is expanding its biologics and large-molecule work in India over the next five years.
The company has secured $100 million from Quadria Capital to build new capabilities in India.
India is becoming an innovation partner for big pharma, with a focus on monoclonal antibodies, ADCs, and other advanced therapies.
Global drugmakers are rebalancing their geographic concentration risks by increasing outsourcing to India.
Aragen is investing in AI, machine learning, and digital platforms, and exploring collaborations with hospitals and clinical institutions.
- Who
- Aragen Life Sciences, a contract research, development, and manufacturing organization (CRDMO)
- What
- Expanding biologics and large-molecule work in India
- Where
- India, with a focus on Hyderabad
- When
- Over the next five years
- Why
- To meet growing demand for complex biologics, ADCs, and high-potency manufacturing, and to rebalance geographic concentration risks
Key facts
- Company
- Aragen Life Sciences
- Backers
- Goldman Sachs, Quadria Capital
- Headquarters
- Hyderabad, India
- Clients
- 15 of the world's top 20 pharmaceutical companies
- Investment
- $100 million from Quadria Capital
- Focus Areas
- Oncology, ADCs, advanced biologics
- Market Projection
- India's CRDMO market projected to grow to $22–25 billion by 2035
Quotes
Manni Kantipudi
Chief Executive Officer of Aragen Life Sciences
“India has been an innovation partner for big pharma for several years now, and this trend will only accelerate with continued investments by both big pharma and the CRDMO industry in newer modalities.”
businesstoday.in
“The big challenge for the industry will be to build talent at scale. Historically, India has been exceptionally strong in chemistry, chemical engineering and process R&D, formulations. What we are doing at Aragen is upscaling this expertise into biology and biologics.”
businesstoday.in
